Heron Therapeutics, Inc. /de/
A biotech company that makes drugs for pain after surgery and for nausea and vomiting tied to chemotherapy. Its U.S.-marketed products include ZYNRELEF, a long-acting local anesthetic for postoperative pain, and CINVANTI and SUSTOL, anti-nausea medicines given to chemotherapy patients. Founded in 1983, the company ran for decades as A.P. Pharma before renaming itself Heron Therapeutics in 2014 as part of a fresh strategic direction and a relisting on the Nasdaq.
Bought 2.39M
Granted 123.7K · Bought 4.25M
Granted 78.37M · Bought 9.87M · Sold 2.69M
Sold 97.2K
Granted 535.6K · Bought 150.0K
Granted 144.4K · Bought 85.0K
Granted 254.1K
Granted 214.6K · Bought 22.1K
Granted 207.2K · Bought 10.0K
Granted 142.6K · Bought 75.0K
Granted 214.3K · Sold 46.9K
Granted 212.3K
Granted 427.8K · Bought 1.01M · Sold 260.0K
Granted 136.8K
Granted 525.0K · Sold 525.0K
Granted 80.9K
Granted 6.7K
Sold 16.0K
Granted 32.6K · Bought 15.0K
Granted 12.8K
Granted 66.6K
Granted 137.9K · Bought 1.4K · Sold 1.2K
Granted 137.9K · Sold 1.0K
Granted 91.8K
Granted 134.9K
Granted 109.8K
Granted 299.3K
Granted 39.9K · Bought 18.1K
Granted 63.1K · Bought 6.9K
Granted 45.7K · Sold 4.4K
Granted 146.2K · Sold 112.1K
Granted 15.0K
Bought 285.7K
Granted 21.0K
Granted 30.0K · Sold 30.0K
Granted 72.2K · Sold 70.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 2 transactions | — | 30.05M | — | 2.39M | — |
| Morgan AdamDirector · 6 transactions | — | 8.88M | 123.7K | 4.25M | — |
| Tang Capital Management LLC +2 co-filers10% owner, Director, 10% owner · 29 transactions | — | 5.85Mas of Sep 2018 | 78.37M | 9.87M | 2.69M |
| Baker Felix +2 co-filers10% owner · 1 transaction | — | 5.27Mas of Jun 2011 | — | — | — |
| Savitr Capital, LLCExiting 10% holder · 26 transactions | — | 1.71Mas of Feb 2015 | — | — | 97.2K |
| Collard Craig AChief Executive Officer, Director · 21 transactions | — | 757.9K | 535.6K | 150.0K | — |
| Duarte IraEVP, Chief Financial Officer · 21 transactions | — | 264.6K | 144.4K | 85.0K | — |
| Whelan JohnCFO · 1 transaction | — | 254.1Kas of Jul 2013 | 254.1K | — | — |
| Turnbull GregDirector · 19 transactions | — | 245.3Kas of May 2010 | 214.6K | 22.1K | — |
| Goddard PaulDirector · 8 transactions | — | 225.9Kas of May 2010 | 207.2K | 10.0K | — |
| Forbes William PEVP, Chief Development Officer · 20 transactions | — | 221.6K | 142.6K | 75.0K | — |
| Rosenblatt TobyDirector · 11 transactions | — | 210.2Kas of May 2010 | 214.3K | — | 46.9K |
| Zerbe Robert L MDDirector · 9 transactions | — | 202.1Kas of May 2010 | 212.3K | — | — |
| Quart Barry DChief Executive Officer, Director · 57 transactions | — | 178.0Kas of Jan 2023 | 427.8K | 1.01M | 260.0K |
| Hensley Mark EarlChief Operating Officer · 2 transactions | — | 136.8K | 136.8K | — | — |
| Rosen RobertPresident, Director · 19 transactions | — | 98.2Kas of Jul 2018 | 525.0K | — | 525.0K |
| Rodriguez SusanDirector · 4 transactions | — | 87.2Kas of Jan 2025 | 80.9K | — | — |
| Drury Stephen ADirector · 9 transactions | — | 84.7Kas of Aug 2006 | 6.7K | — | — |
| Midler Andrew R +1 co-filerExiting 10% holder · 11 transactions | — | 79.2Kas of Feb 2015 | — | — | 16.0K |
| Riepenhausen PeterDirector · 13 transactions | — | 71.9Kas of May 2008 | 32.6K | 15.0K | — |
| Winger Dennis LDirector · 4 transactions | — | 69.5Kas of Aug 2006 | 12.8K | — | — |
| Peraza LisaVP, Chief Accounting Officer · 38 transactions | — | 55.9Kas of Jan 2024 | 66.6K | — | — |
| Christian WaageDirector · 11 transactions | — | 54.0K | 137.9K | 1.4K | 1.2K |
| Johnson Craig ADirector · 10 transactions | — | 54.0K | 137.9K | — | 1.0K |
| Cusack ThomasDirector · 2 transactions | — | 54.0K | 91.8K | — | — |
| Dissanaike SharmilaDirector · 5 transactions | — | 54.0K | 134.9K | — | — |
| Kaseta MichaelDirector · 3 transactions | — | 54.0K | 109.8K | — | — |
| Davis StephenDirector · 9 transactions | — | 52.0Kas of Dec 2022 | 299.3K | — | — |
| Poyhonen JohnPresident & CCO · 32 transactions | — | 48.7Kas of Apr 2023 | 39.9K | 18.1K | — |
| Prentki Ronald JPresident & CEO, Director · 5 transactions | — | 47.4Kas of Jul 2009 | 63.1K | 6.9K | — |
| Szekeres David LeslieEVP, Chief Operating Officer · 34 transactions | — | 35.8Kas of Jul 2023 | 45.7K | — | 4.4K |
| Manhard KimberlyEVP, Drug Development · 57 transactions | — | 29.7Kas of Apr 2023 | 146.2K | — | 112.1K |
| Whiteford StephenV.P., Finance & CFO · 1 transaction | — | 15.0Kas of Dec 2006 | 15.0K | — | — |
| Drazba Brian G.VP, Finance & CFO · 5 transactions | — | 3.8Kas of Oct 2016 | — | — | — |
| Tang Kevin CFormer Director · 21 transactions | — | 3.4Kas of Feb 2021 | — | 285.7K | — |
| Taylor Arthur TDirector · 2 transactions | — | 3.0Kas of May 2008 | 21.0K | — | — |
| Hoffman RobertCFO & SVP, Finance · 5 transactions | — | 2.3Kas of Jul 2018 | 30.0K | — | 30.0K |
| Marshall PaulSVP, Technical Operations · 5 transactions | — | 2.2Kas of Mar 2016 | 72.2K | — | 70.0K |
| Baker Felix +2 co-filers10% owner · 1 transaction | — | 0as of Jun 2011 | — | — | — |
| SPCH, LLC10% owner · 1 transaction | — | 0as of Jan 2013 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +14.33M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.